The Managed Care Review Board^® - Examining the Impact of Cardiovascular Safety with Emerging Treatments for Type 2 Diabetes Web Activity

• Chapter 1: Applying Cardiovascular Outcomes Trials in Type 2 Diabetes to the Managed Care Setting
• Chapter 2: Treatment Algorithms, Plan Benefit Designs, and Patient-Centered Strategies with Recent CVOT Trial Data
  
  • Release Date: December 22, 2017
  • Expiration Date: June 30, 2019
  • Estimated Time to Complete Activity: 0.75 hours per chapter
  • Compatible with all modern browsers and mobile devices

REVIEW BOARD FACULTY

John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health Click here for biography Jennifer Green, MD Associate Professor of Medicine Duke University Medical Center Division of Endocrinology Chief, Endocrine Section Durham VA Medical Center Click here for biography Curtis Triplitt, PharmD, CDE Texas Diabetes Institute University Health Systems Associate Professor of Medicine, Clinical Division of Diabetes University of Texas Health Science Center at San Antonio Click here for biography Vanita K. Pindolia, PharmD, BCPS, MBA Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography

TARGET AUDIENCE

• Medical directors and pharmacy directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with type 2 diabetes including: physicians, pharmacists, and registered nurses

STATEMENT OF NEED/PROGRAM OVERVIEW

Diabetes is the seventh leading cause of mortality in the United States and a significant contributor to the development of cardiovascular disease and stroke. Prospective epidemiological and experimental studies have reported an association between suboptimal glycemic control as measured by an elevated glycated hemoglobin and both micro- and macrovascular complications. Individuals with type 2 diabetes mellitus (T2DM) have a 3-fold increase in cardiovascular mortality and a 2-fold increase in overall mortality compared to age-matched peers without T2DM.

These observations suggest there is a clear need to develop therapeutic strategies to mitigate disease progression as well as reduce the cardiovascular disease burden.

EDUCATIONAL OBJECTIVES

• Recognize the rationale for cardiovascular outcomes trials (CVOT) in T2DM and review data from recent CVOT of anti-hyperglycemic agents
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

• Examine alignment of managed care T2DM treatment algorithms with recent CVOT trial data
• Implement patient-centered strategies to minimize cardiovascular risk in patients treated in a managed care setting
• Discuss the potential impact of CVOT results on benefit design strategies

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Chapter 1: 0.75 CME credits
• Chapter 2: 0.75 CME credits

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

• Chapter 1: UAN JA4008162-9999-19-735-H01-P, 0.75 contact hours (knowledge)
• Chapter 2: UAN JA4008162-9999-19-736-H01-P, 0.75 contact hours (knowledge)

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

• Chapter 1: 0.6 contact hours
• Chapter 2: 0.6 contact hours

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 22, 2017, through June 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.